US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab
Posted on17 Jul 2019
Tagscrizanlizumab, MAB, monoclonal antibody, priority review, Priority Review Designation, USFDA Priority Review
Comments0
Novartis announced the US Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) and has granted Priority Review for... Read More
Novartis R&D portfolio update
Posted on06 Nov 2018
Tagsbrolucizumab, canikinumab, cosentyx, crizanlizumab, Entresto, Gilenya, novartis, NSCLC, ofatumumab, R&D portfolio
Comments0
Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline.... Read More